ACTG 081 shows TMP/SMX, aerosolized pentamidine, dapsone have "similar effectiveness" in PCP prevention.
TMP/SMX, AEROSOLIZED PENTAMIDINE, DAPSONE SHOW "SIMILAR EFFECTIVENESS" in preventing Pneumocystis carinii pneumonia in patients with advanced HIV disease, according to results of the National Institute of Allergy & Infectious Diseases' AIDS Clinical Trials Group protocol 081. The estimated 36-month cumulative risks of PCP in the TMP/SMX, dapsone and aerosolized pentamidine groups are 18%, 17% and 21%, respectively, the investigators found. TMP/SMX is marketed by Hoffmann-La Roche as Bactrim, by Burroughs Wellcome as Septra and in generic versions. Aerosolized pentamidine is marketed by Fujisawa as NebuPent.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth